MARKET

PSTI

PSTI

Pluristem
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.810
-0.330
-7.97%
Opening 12:55 03/31 EDT
OPEN
4.060
PREV CLOSE
4.140
HIGH
4.180
LOW
3.770
VOLUME
720.88K
TURNOVER
--
52 WEEK HIGH
9.72
52 WEEK LOW
2.820
MARKET CAP
68.05M
P/E (TTM)
-0.4753
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of PSTI and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average PSTI stock price target is 15.13 with a high estimate of 25.00 and a low estimate of 8.00.

EPS

PSTI News

More
  • AMRN, CCL among premarket losers
  • Seeking Alpha - Article · 3h ago
  • Pluristem treats first three COVID-19 patients in Israel; shares up 11% premarket
  • Seeking Alpha - Article · 1d ago
  • Pluristem Treated First Three COVID-19 Patients in Israel under Compassionate Use
  • GlobeNewswire · 1d ago
  • Pluristem updates on business amid COVID-19
  • seekingalpha · 4d ago

Industry

Biotechnology & Medical Research
-1.40%
Pharmaceuticals & Medical Research
-0.43%

Hot Stocks

Symbol
Price
%Change

About PSTI

Pluristem Therapeutics Inc. is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company's lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome. Its operations are focused on the research, development, clinical trials and manufacturing of cell therapeutics and related technologies. The Company's products include PLX-PAD and PLX R18. The Company's PLX cells are adherent stromal cells (ASCs) that are expanded using a three dimensional (3D) process. The system utilizes a synthetic scaffold to create an artificial 3D environment where placental-derived stromal cells can grow. The Company's PLX products are administered using a standard needle and syringe. The Company's PLX products are in clinical-stage development for multiple indications, such as cardiovascular, orthopedic, pulmonary and women's health diseases.
More

Webull offers kinds of Pluristem Therapeutics Inc. stock information, including NASDAQ:PSTI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PSTI stock news, and many more online research tools to help you make informed decisions.